Vicente Anido Jr
CIK 1207633 · Chief Executive Officer · last filed 2021-02-25
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
AERI price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
CORONA DEL MAR, CA 92625
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| AERIE PHARMACEUTICALS INC (AERI) Delisted | Chief Executive Officer | 243,896 | $15.25 | $3.72M | -$11.66M | 22 | 2021-02-25 |
| Assertio Therapeutics, Inc (DEPO) Delisted | Director | 4,403 | — | — | $0 | 6 | 2016-05-13 |
| QLTI | Director | — | $28.01 | — | $0 | 2 | 2013-07-17 |
| ISTA PHARMACEUTICALS INC (ISTA) Delisted | President & CEO | 500,659 | — | — | $315.1K | 23 | 2012-05-10 |
| AHG | Director | 5,333 | $1.35 | $7.2K | $0 | 1 | 2007-05-07 |
Recent Filings · Page 2 of 6
56 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2019-02-26 | AERIE PHARMACEUTICALS INC (AERI) Delisted | Tax (F) | −4,142 | -$166.1K | EDGAR |
| 2019-02-11 | AERIE PHARMACEUTICALS INC (AERI) Delisted | Mixed | +23,789 | -$65.6K | EDGAR |
| 2018-06-13 | AERIE PHARMACEUTICALS INC (AERI) Delisted | Mixed | — | -$2.94M | EDGAR |
| 2018-06-08 | AERIE PHARMACEUTICALS INC (AERI) Delisted | Mixed | — | -$8.90M | EDGAR |
| 2018-05-10 | AERIE PHARMACEUTICALS INC (AERI) Delisted | Tax (F) | −4,457 | -$240.0K | EDGAR |
| 2018-04-16 | AERIE PHARMACEUTICALS INC (AERI) Delisted | Mixed | +18,299 | -$168.2K | EDGAR |
| 2018-02-12 | AERIE PHARMACEUTICALS INC (AERI) Delisted | Grant (A) | +25,413 | $0 | EDGAR |
| 2017-02-27 | AERIE PHARMACEUTICALS INC (AERI) Delisted | Mixed | +14,047 | -$144.1K | EDGAR |
| 2016-05-13 | Assertio Therapeutics, Inc (DEPO) Delisted | Tax (F) | −1,035 | -$18.1K | EDGAR |
| 2016-03-01 | AERIE PHARMACEUTICALS INC (AERI) Delisted | Grant (A) | +25,085 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.